DelveInsight has launched a new report on “IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “IgA Nephropathy (IgAN) – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the IgA Nephropathy (IgAN) , historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts:
Scope of the Report:
Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market
IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease.
People who have this condition most often present with one or recurrent episodes of having blood in their urine (visible hematuria). These episodes usually occur during or right after an upper respiratory tract infection such as a cold, sore throat or a gastrointestinal infection.
IgA nephropathy usually doesn’t cause symptoms in the early stages, so the disease can go unnoticed for years or decades. It’s sometimes suspected when routine tests reveal protein and red blood cells in your urine that can’t be seen without a microscope (microscopic hematuria). In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria, or blood in the urine. Hematuria can be a sign of damaged glomeruli. Blood in the urine may appear during or soon after a cold, sore throat, or other respiratory infection. The amount of blood may be: visible with the naked eye. The urine may turn pink or the color of tea or cola. Sometimes a person may have dark or bloody urine so small that it can only be detected using special medical tests.
Another symptom of IgA nephropathy is albuminuria—when a person’s urine contains an increased amount of albumin, a protein typically found in the blood, or large amounts of protein in the urine.
Key Companies Covered:
Some of the Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of IgA Nephropathy (IgAN)
3. Competitive Intelligence Analysis for IgA Nephropathy (IgAN)
4. IgA Nephropathy (IgAN) : Market Overview at a Glance
5. IgA Nephropathy (IgAN) : Disease Background and Overview
6. Patient Journey
7. IgA Nephropathy (IgAN) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of IgA Nephropathy (IgAN) Treatment
11. Marketed Products
12. Emerging Therapies
13. IgA Nephropathy (IgAN) : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of IgA Nephropathy (IgAN)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/iga-nephropathy-igan-market